Dipeptidyl peptidase 4 inhibitors and bullous pemphigoid − more evidence of a link: a report of three cases


  • Amrita Randhawa Department of Dermatology, Queen Elizabeth University Hospital, Glasgow
  • Donna Torley Department of Dermatology, Queen Elizabeth University Hospital, Glasgow
  • Alastair Kerr Department of Dermatology, Queen Elizabeth University Hospital, Glasgow
  • Grant Wylie Department of Dermatology Queen Elizabeth University Hospital Glasgow




oral anti-hyperglycaemic agent, bullous pemphigoid, DPP-4 inhibitors


Recently, dipeptidyl peptidase 4 (DPP-4) inhibitors, an antidiabetic medication, have been implicated in the development of bullous pemphigoid, the most common autoimmune cutaneous blistering disorder. In this report we present three cases of DPP-4 associated bullous pemphigoid in our dermatology department. These cases illustrate the importance for clinicians to consider a drug as a trigger for bullous pemphigoid in elderly patients with diabetes.


Schmidt E, Zillikens D. Pemphigoid diseases. Lancet 2013;381(9863): 320−32. https://doi.org/10.1016/S0140-6736(12)61140-4

Hung CT, Liu JS, Cheng CY, et al. Increased risk of bullous pemphigoid in dipeptidyl peptidase 4 inhibitors: a nationwide, population‐based, cohort study in Taiwan. J Dermatol 2020;47(3):245−50. https://doi.org/10.1111/1346-8138.15195

Bene J, Moulis G, Bennani I, et al, French Association of Regional PharmacoVigilance Centres. Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case–noncase study in the French Pharmacovigilance Database. Br J Dermatol 2016;175(2):296−301. https://doi.org/10.1111/bjd.14601

García M, Aranburu MA, Palacios‐Zabalza I, Lertxundi U, Aguirre C. Dipeptidyl peptidase‐IV inhibitors induced bullous pemphigoid: a case report and analysis of cases reported in the European Pharmacovigilance Database. J Clin Pharm Ther 2016;41(3):368−70. https://doi.org/10.1111/jcpt.12397

Izumi K, Nishie W, Mai Y, et al. Autoantibody profile differentiates between inflammatory and noninflammatory bullous pemphigoid. J Invest Dermatol 2016;136(11):2201−10. https://doi.org/10.1016/j.jid.2016.06.622

Nishie W. Dipeptidyl peptidase IV inhibitor-associated bullous pemphigoid: a recently recognized autoimmune blistering disease with unique clinical, immunological and genetic characteristics. Immunol Med 2019;42(1):22−8. https://doi.org/10.1080/25785826.2019.1619233






Case Reports